In the 9 years since the publication of our 2011 review of targeted treatment of thyroid cancer
with multikinase inhibitors, much has changed in the landscape of this heterogeneous …

Thyroid carcinoma is the most common cancer in the endocrine system. Recent advances,
using next-generation sequencing, have shed light on the molecular pathogenesis of thyroid …

Background Approximately 25% of thyroid nodule fine‐needle aspirates (FNAs) have
cytology that is indeterminate for malignant disease. Accurate risk stratification of these …

Thyroid cancer comprises different clinical and histological entities. Whereas differentiated
(DTCs) malignancies are sensitive to radioiodine therapy, anaplastic (ATCs) and medullary …

Background: The prognosis of advanced or metastatic medullary thyroid carcinoma (MTC) is
poor, and there are few therapeutic options. Anlotinib has previously shown promising …

Selpercatinib is a first-in-class, highly selective and potent, central nervous system-active
RET kinase inhibitor. In the phase I/II trial, selpercatinib demonstrated clinically meaningful …

The worldwide incidence of thyroid malignancies has been increasing rapidly. Sensitive
imaging modalities and early detection of thyroid lesions have made thyroid cancers the …

Thyroid cancer, a cancerous tumor or growth located within the thyroid gland, is the most
common endocrine cancer. It is one of the few cancers whereby incidence rates have …

Incidence of endocrine cancers is rising every year. Over the last decade, evidence has
accumulated that demonstrates the anti-cancer effects of an anti-diabetic drug-metformin-in …

Simple Summary Medullary thyroid cancer derives from calcitonin-producing C cells and is
characterized by sporadic and familial RET-mutated forms. Serum calcitonin represents the …